NeurOp Overview
- Year Founded
-
2002
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
NeurOp General Information
Description
Developer of medicines designed to treat central nervous system disorders. The company develops medicines for central nervous system disorders, including severe pain, subarachnoid hemorrhage, and catastrophic juvenile epilepsies, and its technology targets the subunit of neuronal receptors and their potential therapeutic benefit, enabling patients to treat their pain, stroke, hemorrhage, and treatment-resistant depression.
Contact Information
Website
www.neuropinc.comCorporate Office
- 58 Edgewood Avenue, North East
- 1st Floor, Suite 122
- Atlanta, GA 30303
- United States
Corporate Office
- 58 Edgewood Avenue, North East
- 1st Floor, Suite 122
- Atlanta, GA 30303
- United States
NeurOp Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Secondary Transaction - Private | 01-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 13. Grant | 04-Feb-2019 | Completed | Clinical Trials - Phase 1 | |||
| 12. Later Stage VC | Cancelled | Clinical Trials - Phase 1 | ||||
| 11. Grant | 01-Jul-2017 | Completed | Clinical Trials - Phase 1 | |||
| 10. Grant | 29-Sep-2014 | Completed | Clinical Trials - General | |||
| 9. Seed Round | 17-Feb-2014 | Completed | Clinical Trials - General | |||
| 8. Grant | 15-Apr-2013 | Completed | Clinical Trials - General | |||
| 7. Grant | 06-Sep-2012 | Completed | Clinical Trials - General | |||
| 6. Grant | 01-Jan-2011 | $3.67M | $635K | Completed | Clinical Trials - General | |
| 5. Angel (individual) | 01-Jan-2011 | $135K | $635K | Completed | Clinical Trials - General |
NeurOp Comparisons
Industry
Financing
Details
NeurOp Competitors (23)
One of NeurOp’s 23 competitors is Johnson&Johnson Innovative Medicine, a Venture Capital-Backed company based in Raritan, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Johnson&Johnson Innovative Medicine | Venture Capital-Backed | Raritan, NJ | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Achelios Therapeutics | Venture Capital-Backed | Durham, NC | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
NeurOp Patents
NeurOp Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022339672-A1 | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph | Active | 02-Sep-2021 | ||
| AU-2022339672-B2 | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph | Active | 02-Sep-2021 | ||
| CA-3230601-A1 | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph | Pending | 02-Sep-2021 | ||
| EP-4395783-A1 | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph | Pending | 02-Sep-2021 | ||
| EP-4395783-A4 | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph | Pending | 02-Sep-2021 | C07D295/135 |
NeurOp Signals
NeurOp Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Neurological Disorders and Stroke | Government | |||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Georgia Research Alliance | Not-For-Profit Venture Capital | Minority | ||
| Advanced Technology Development Center | Accelerator/Incubator | Minority | ||
| Ariel Savannah Angel Partners | Angel Group | Minority |
NeurOp FAQs
-
When was NeurOp founded?
NeurOp was founded in 2002.
-
Where is NeurOp headquartered?
NeurOp is headquartered in Atlanta, GA.
-
What is the size of NeurOp?
NeurOp has 6 total employees.
-
What industry is NeurOp in?
NeurOp’s primary industry is Drug Discovery.
-
Is NeurOp a private or public company?
NeurOp is a Private company.
-
What is NeurOp’s current revenue?
The current revenue for NeurOp is .
-
How much funding has NeurOp raised over time?
NeurOp has raised $790K.
-
Who are NeurOp’s investors?
National Institutes of Neurological Disorders and Stroke, Bristol-Myers Squibb, Georgia Research Alliance, Advanced Technology Development Center, and Ariel Savannah Angel Partners are 5 of 6 investors who have invested in NeurOp.
-
Who are NeurOp’s competitors?
Johnson&Johnson Innovative Medicine, Voyager Therapeutics, Cognition Therapeutics, Achelios Therapeutics, and Gilead are some of the 23 competitors of NeurOp.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process